---
title: "Freedom Capital Markets maintains Buy rating on Astrana Health, $50 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300683297.md"
description: "Freedom Capital Markets maintained a Buy rating on Astrana Health with a $50 price target, implying 40.6% upside from the Sep 30 close of $35.57. The firm cites strong revenue growth potential, noting a 15% increase in legacy operations for Q1 2026. Despite challenges like a short-seller report and cybersecurity incident, Astrana's resilience and solid fundamentals support the positive outlook."
datetime: "2026-10-01T12:17:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300683297.md)
  - [en](https://longbridge.com/en/news/300683297.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300683297.md)
generator: "portal-rs"
---

# Freedom Capital Markets maintains Buy rating on Astrana Health, $50 price target

Freedom Capital Markets maintained their Buy rating on Astrana Health's stock with a price target of $50.00.

The price target implies an upside of 40.6% from the Sep 30 close of $35.57.

**Key takeaways from the analyst note**

**Strong Revenue Growth Potential**: Astrana Health has demonstrated a robust revenue growth trajectory, particularly in its legacy operations, which showed a 15% increase on a constant-entity basis in Q1 2026, indicating a solid foundation for future performance despite temporary setbacks from acquisitions.

**Resilience Amid Challenges**: The company has effectively managed to maintain its Buy rating even in the face of recent negative events, such as a short-seller report and a cybersecurity incident, suggesting strong underlying fundamentals that can withstand external pressures, providing confidence in its long-term outlook.

Explore more price target data and ratings for Astrana Health on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ASTH.US](https://longbridge.com/en/quote/ASTH.US.md)
- [FRHC.US](https://longbridge.com/en/quote/FRHC.US.md)

## Related News & Research

- [Astrana Health Detects Unusual Activity In Subsidiary Environment - SEC Filing](https://longbridge.com/en/news/299893622.md)
- [CrowdStrike Holdings (CRWD) Joins OpenAI Marketplace, Is The Stock Now Too Pricey?](https://longbridge.com/en/news/300880924.md)
- [ROI-Oil's new problem isn't supply. It's logistics: Bousso](https://longbridge.com/en/news/300903866.md)
- [3 Stocks with Strong Buy Ratings and Double-Digit Upside](https://longbridge.com/en/news/300907721.md)
- [Nvidia Stock Forecast: Here's How High Morgan Stanley Thinks NVDA Can Go](https://longbridge.com/en/news/300895298.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**